PRTC · Categories · M&A
PRTC - Mergers and acquisitions
PureTech Health plc (PRTC) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for PRTC
- Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 MillionRoyalty Pharma has acquired an interest in PureTech's royalty in Karuna Therapeutics' KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholdsPureTech retains its current equity stake in Karuna in addition to milestone payments and 20% of sublicense revenues due to PureTechTransaction provides further non-dilutive capital for PureTech's growing and rapidly advancing Wholly Owned Pipeline, with five clinical-stage candidates expected by the end of 2023 NEW YORK and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences in
- PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 MillionRoyalty Pharma has acquired an interest in PureTech's royalty in Karuna Therapeutics' KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds. PureTech retains its current equity stake in Karuna in addition to milestone payments and 20% of sublicense revenues due to PureTech. Transaction provides further non-dilutive capital for PureTech's growing and rapidly advancing Wholly Owned Pipeline, with five clinical-stage candidates expected by the end of 2023. PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, and R
- PureTech Acquires Remaining Interest in Founded Entity Alivio TherapeuticsOral IL-22 and other preclinical therapeutic candidates as well as the underlying technology platform to be integrated in the Company's Wholly Owned Pipeline PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the acquisition of the remaining 22 percent of shares outstanding in its Founded Entity, Alivio Therapeutics ("Alivio"). Alivio's therapeutic candidates, in development for inflammatory disorders including inflammatory bowel disease (IBD), will be integrated into the Company's Wholly Owned